Differential avidity determination of IgG directed towards the receptor-binding domain (RBD) of SARS-CoV-2 wild-type and its variants in one assay: Rational tool for the assessment of protective immunity.

Bauer, Georg; Struck, Friedhelm; Staschik, Eva; Maile, Julia; Wochinz-Richter, Karin; Motz, Manfred; Soutschek, Erwin

Bauer, Georg; Struck, Friedhelm; Staschik, Eva; Maile, Julia; Wochinz-Richter, Karin; Motz, Manfred; Soutschek, Erwin.

Afiliação

Bauer G; Institute of Virology, Medical Center, University of Freiburg, Freiburg, Germany.
Struck F; Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Staschik E; Mikrogen GmbH, Neuried, Germany.
Maile J; Mikrogen GmbH, Neuried, Germany.
Wochinz-Richter K; Mikrogen GmbH, Neuried, Germany.
Motz M; Mikrogen GmbH, Neuried, Germany.
Soutschek E; Mikrogen GmbH, Neuried, Germany.

J Med Virol ; 94(11): 5294-5303, 2022 11.

Article em En | MEDLINE | ID: mdl-35851961

Assuntos

COVID-19; SARS-CoV-2; Anticorpos Antivirais; COVID-19/diagnóstico; Humanos; Imunoglobulina G; SARS-CoV-2/genética; Glicoproteína da Espícula de Coronavírus/genética

Palavras-chave

SARS-CoV-2; avidity; omicron variant; protective immunity; receptor-binding domain; recom Line SARS-CoV-2 IgG

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google